Accreditation Language

A user account is required in order to view the educational content on this website. Please click here to create an account or to login.

EDUCATIONAL PROGRAM 1 - OVERVIEW OF ANTICOAGULATION REVERSAL AND PATIENT SIMULATION DEMONSTRATION

Target Audience

This enduring educational program is intended for physicians, pharmacists, and other healthcare Professionals involved in with patients impacted by anticoagulation therapy.

Educational Goal/Purpose

The Overview of Anticoagulation Reversal and Patient Simulation Demonstration is designed to enable participants to observe the impact of anticoagulation management in the simulation environment, addressing the need for added knowledge and experience in managing these frequently challenging patients.

Learning Objectives

• Apply evidence-based approaches to the diagnostic and therapeutic management of patients with NOAC or warfarin-related major bleeding and pre-procedural bleeding concerns

• Develop a specific treatment protocol for the evaluation and management of dabigatran- or warfarin-related major bleeding and pre-procedural bleeding concerns

• Differentiate between vitamin K administration and immediate factor repletion in warfarin-treated patients with bleeding emergencies

• Explain the mechanism of action and rationale for use of both idarucizumab and 4-factor prothrombin complex concentrate in the management of bleeding emergencies

Initial Release Date: January 1, 2017

End Date: January 1, 2018

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and CE Symmetry and Hospital Quality Foundation. The CMEsolutions is accredited by the ACCME to provide continuing medical education for physicians.

The CMEsolutions designates this online enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The CMEsolutions is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for .75 contact hours (0.075 CEUs). ACPE Program Number: 0274-9999-17-001-H04-P

Fees

There is no fee for participation in this accredited educational activity.

Participation Requirements

1. View/participate in educational program

2. Complete session evaluation and credit request form

3. Receive emailed copy of certificate within 7-10 business days

4. Pharmacy credit will be submitted to NABP once participation has been verified with participant’s NABP number and date of birth (MM/DD)

Planner Disclosures

No member of CMEsolutions or CE Symmetry or Hospital Quality Foundation has any financial relationships to disclose relevant to this activity.

Faculty and Disclosures

CMEsolutions has resolved all conflicts of interest prior to this educational activity through the following procedures:

• All potential conflicts have been discussed with the speakers and all have agreed to the Conflict of Interest policy

• All presentations have been peer reviewed for conflict or bias

• All participants have signed a disclosure statement indicating they will present information fairly and without bias

Faculty

Charles Pollack, MD

Professor of Emergency Medicine, Sidney Kimmel School of Medicine, Thomas Jefferson University

Philadelphia, PA

Charles Pollack discloses the following relevant financial relationships:

No promotional activities
Consultant for Boehringer Ingelheim, Bristol-Myers Squibb / Pfizer, and Janssen Pharmaceuticals
Grant/Research Support from Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, and Portola Pharmaceuticals

Off-label Use

Overview of Anticoagulation Reversal and Patient Simulation Demonstration may contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA. Please consult the prescribing information for each product.

Commercial Support

Commercial support for this educational activity is provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Privacy Policy

CMEsolutions Privacy and Confidentiality Policy: www.online-med-edu.com/privacypolicy.pdf

CMEsolutions can be contacted at info@cmesolutions.org.

EDUCATIONAL PROGRAMS 2 - 4 - BODY INTERACT PATIENT SIMULATION CASES
NOTE: THESE CASES ALL HAVE THE SAME TARGET AUDIENCE AND LEARNING OBJECTIVES.
THERE ARE DIFFERENT ACPE ACCREDITATION NUMBERS

EDUCATIONAL PROGRAM 2 - JOHN SMITH - CARDIOVERSION WHILE ON DABIGATRAN

EDUCATIONAL PROGRAM 3 - AYDEN REEVE - ANTICOAGULATED PATIENT REQUIRING URGENT SURGERY

EDUCATIONAL PROGRAM 4 - LANEY OLIVERSON - HIP FRACTURE IN PERMANENT AF

Target Audience

This enduring educational program is intended for physicians, pharmacists, and other healthcare providers involved with patients impacted by anticoagulation therapy.

Educational Goal/Purpose

The Cardioversion While on Dabigatran – Case #3 is designed to enable participants to observe the impact of anticoagulation management in the simulation environment, addressing the need for added knowledge and experience in managing these frequently challenging patients.

Learning Objectives

1. Develop and implement a specific treatment protocol for the evaluation and management of NOAC or warfarin-related major bleeding and pre-procedural bleeding concerns

2. Differentiate between vitamin K administration versus Non-vitamin K Oral Antagonist administration and the impact of each on the need immediate factor repletion or a specific reversal agent in anticoagulated patients with bleeding emergencies

3. Explain the mechanism of action and rationale for use of both idarucizumab and 4-factor prothrombin complex concentrate in the management of bleeding emergencies

Initial Release Date: January 1, 2017 End Date: January 1, 2018

Accreditation

Fees

There is no fee for participation in this accredited educational activity.

Participation Requirements

1. View/participate in educational program

2. Complete session evaluation and credit request form

3. Receive emailed copy of certificate within 7-10 business days

4. Pharmacy credit will be submitted to NABP once participation has been verified with participant’s NABP number and date of birth (MM/DD)

Planner Disclosures

No member of CMEsolutions or CE Symmetry or Hospital Quality Foundation has any financial relationships to disclose relevant to this activity.

Faculty and Disclosures

CMEsolutions has resolved all conflicts of interest prior to this educational activity through the following procedures:

• All potential conflicts have been discussed with the speakers and all have agreed to the Conflict of Interest policy

• All presentations have been peer reviewed for conflict or bias

• All participants have signed a disclosure statement indicating they will present information fairly and without bias

Faculty

This educational program is a patient-based case study presentation with no faculty.

Off-label Use

Cardioversion While on Dabigatran – Case #3 may contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA. Please consult the prescribing information for each product.

Commercial Support

Commercial support for this educational activity is provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Privacy Policy

CMEsolutions Privacy and Confidentiality Policy: www.online-med-edu.com/privacypolicy.pdf

CMEsolutions can be contacted at info@cmesolutions.org.

Accreditation Language

EDUCATIONAL PROGRAM 1 - OVERVIEW OF ANTICOAGULATION REVERSAL AND PATIENT SIMULATION DEMONSTRATION

EDUCATIONAL PROGRAMS 2 - 4 - BODY INTERACT PATIENT SIMULATION CASESNOTE: THESE CASES ALL HAVE THE SAME TARGET AUDIENCE AND LEARNING OBJECTIVES. THERE ARE DIFFERENT ACPE ACCREDITATION NUMBERS

EDUCATIONAL PROGRAMS 2 - 4 - BODY INTERACT PATIENT SIMULATION CASES
NOTE: THESE CASES ALL HAVE THE SAME TARGET AUDIENCE AND LEARNING OBJECTIVES.
THERE ARE DIFFERENT ACPE ACCREDITATION NUMBERS